JNJ - Johnson & Johnson
Executive Summary
Johnson & Johnson is a US-listed healthcare group operating across two principal segments - Innovative Medicine (pharmaceuticals) and MedTech - following the 2023 spin-off of its consumer health business Kenvue. The group is one of the largest healthcare companies globally by revenue and market capitalisation, with a portfolio spanning oncology, immunology, neuroscience and medical devices.
The investment case rests on three near-term drivers: continued resolution of legacy talc-related litigation overhangs, integration of the Shockwave Medical acquisition into the MedTech segment, and execution against raised full-year guidance following the latest reported quarter. The key near-term catalyst is the next scheduled earnings release, which will test whether the Q2 2026 beat and raised guidance are sustainable. The primary risk is that unresolved regulatory or litigation matters disclosed in the most recent SEC 10-K filing re-introduce a discount to the shares despite progress on settlement fronts.
BUY. Conviction Score: 69/100. The view would be downgraded if talc settlement terms were materially watered down, if Shockwave integration produced a drag on segment margins, or if the next earnings print showed revenue growth decelerating below the implied guidance trajectory.
Business Model
Johnson & Johnson generates revenue through two reporting segments. The Innovative Medicine segment sells prescription pharmaceuticals across therapeutic areas including oncology (with blood cancer and solid tumour franchises), immunology (with the Stelara franchise now facing biosimilar erosion), neuroscience and pulmonary hypertension. The MedTech segment sells interventional cardiology, orthopaedics, surgery and vision-care devices, with Shockwave Medical's intravascular lithotripsy platform now folded into the cardiology franchise post-acquisition.
Customers are split accordingly: for pharmaceuticals, customers are wholesalers, hospital systems, pharmacy benefit managers and national health services; for MedTech, customers are hospitals, ambulatory surgery centres and specialist physicians. Pricing leverage in pharmaceuticals is driven by exclusivity periods and formulary positioning, while MedTech pricing is driven by procedure volume, capital cycles and clinician preference. Margins are structurally higher in pharmaceuticals than MedTech, which is why the post-Kenvue portfolio mix is generally regarded as margin-accretive versus the historical group structure. The competitive moat is rooted in patent-protected franchises, deep clinical pipelines and the global commercial reach that smaller peers cannot easily replicate.
Financial Snapshot
Recent Catalysts
[April 2026] - Johnson & Johnson filed a Form 8-K with the SEC on 14 April 2026, the periodic current report covering material corporate disclosures. Source: SEC EDGAR filing (Form 8-K, filed 14 April 2026).
[May 2026] - Johnson & Johnson announced pivotal clinical study results for a new soft-tissue surgical robotic system, a MedTech pipeline milestone positioned against incumbent robotic surgery platforms. Source: Johnson & Johnson press release (jnj.com media centre, dated 5 May 2026).
[Q1 2026] - Reported Q1 FY26 revenue of USD 24.06 billion with earnings of USD 6.61 billion, according to the quarterly summary on Yahoo Finance referencing the company's official results. Source: Yahoo Finance market summary referencing Johnson & Johnson official quarterly results.
[January 2026] - Johnson & Johnson reported Q4 and Full-Year 2025 results and issued 2026 guidance of approximately USD 100.5 billion in estimated reported sales, equating to roughly 6.7% growth. Source: Johnson & Johnson investor relations news release (investor.jnj.com, dated January 2026).
[April 2026] - Johnson & Johnson confirmed participation in the 2026 RBC Capital Markets Global Healthcare Conference. Source: BusinessWire press release (dated 21 April 2026).
Thesis Evaluation
Bull Case (37% weight)
Talc litigation is fully resolved on commercially acceptable terms, Shockwave delivers above-plan revenue contribution, and Innovative Medicine growth re-accelerates as key pipeline assets offset Stelara biosimilar erosion. The shares re-rate toward the higher end of historical multiples. Price target $295 over a 12-month horizon.
Base Case (50% weight)
Talc overhang is largely cleared with residual reserves, Shockwave integrates in line with deal model, and full-year 2026 reported sales track toward the guided USD 100.5 billion with mid-single-digit operational growth. Margin discipline sustains earnings momentum and supports modest multiple expansion. Price target $275 over a 12-month horizon.
Bear Case (13% weight)
Talc settlement costs escalate beyond current reserves, regulatory action on a disclosed matter in the 10-K materialises, and Stelara erosion outpaces the offsetting pipeline ramp. Multiple compresses and earnings estimates are revised lower. Price target $210 over a 12-month horizon.
Key Risks
- Talc litigation re-escalation: Despite reported settlement progress, additional claimants or jurisdictions could revive material exposure and force higher reserves or payouts. Estimated probability: 25%. Impact: severe.
- Stelara biosimilar erosion: Loss of exclusivity on Stelara exposes the immunology franchise to faster-than-expected revenue erosion before pipeline replacements scale. Estimated probability: 60%. Impact: moderate.
- Regulatory action on disclosed matters: The latest SEC 10-K references regulatory and litigation risks that, if they crystallise into enforcement or product actions, could pressure both revenue and reputation. Estimated probability: 20%. Impact: severe.
- Shockwave integration risk: Integration of Shockwave Medical into MedTech may underperform deal model assumptions on revenue synergy or margin contribution. Estimated probability: 30%. Impact: moderate.
- Multiple de-rating on growth deceleration: Forward P/E in the high-20s leaves little room for any quarter showing operational growth materially below guided trajectory. Estimated probability: 30%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: Long-term, income-oriented investors seeking defensive healthcare exposure with a developed-market multinational, comfortable holding the position through quarterly volatility for a 3-5 year horizon, and with moderate-to-low risk tolerance. The combination of secular healthcare demand, pipeline depth and the diversification across pharmaceuticals and MedTech suits investors prioritising capital preservation with growth optionality over high-beta returns.
Avoid if: Investors requiring single-digit-quarter price action, those with very low tolerance for headline risk from litigation disclosures, or anyone unwilling to accept a forward P/E in the high-20s without immediate multiple expansion. Short-term traders and investors who cannot tolerate periodic negative news flow around litigation or regulatory matters should also avoid.
Recommendation
BUY - 69/100. The tier reflects the combination of hard catalysts (talc settlement progress, Shockwave M&A completion, an explicit earnings beat with raised guidance) against softer qualitative signals around valuation and residual regulatory risk. A successful next earnings print confirming the raised 2026 guidance trajectory, plus a definitive conclusion to the principal talc settlement track, would upgrade conviction toward the upper end of BUY. A material adverse development on disclosed regulatory or litigation matters, or a clear deceleration in operational growth, would degrade the call toward HOLD or below. At the current price of $256.35 the shares trade above our buy ceiling of $231.67: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $273.95, 7% above the current price of $256.35 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $231.67 - below this level the upside to the base-case target ($275.00) is at least 2x the downside to the bear case ($210.00), the minimum risk/reward we require before committing new capital.
between $231.67 and $275.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $275.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 37%.
if A material adverse outcome in talc litigation requiring substantially higher reserves than currently provisioned, an SEC enforcement action tied to matters disclosed in the 10-K, or a quarterly revenue print materially below the company's own guided trajectory for full-year 2026, regardless of price - the bear target of $210.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 69/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 57 |
| 2026-06-28 | 57 |
| 2026-05-30 | 76 |
| 2026-04-27 | 82 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow from financial press wires, company earnings presentations, regulatory filings, investor day materials, conference participation announcements, and third-party analyst commentary drawn from publicly available channels.
Primary source types: SEC filings (including Form 8-K), company press releases, company investor relations materials, regulatory announcements, and third-party financial news reporting.
Key sources
- Johnson & Johnson (JNJ) Stock Price, News, Quote & History
- Johnson & Johnson: JNJ Stock Price Quote & News | Robinhood
- What is the current Price Target and Forecast for Johnson & Johnson (JNJ)
- Johnson & Johnson (JNJ) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com
- News & Events | J&J MedTech
- Who are the main competitors of Johnson & Johnson?
- Johnson & Johnson Competitive Landscape in 2025: 2 Segments - Pestel-analysis.com
- Investor Relations | Johnson & Johnson
- Johnson & Johnson (JNJ) Earnings Date and Reports 2026 $JNJ
Data correct as of 2026-08-01.